We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Neurological Disorder Linked to Genetic Mutations

By LabMedica International staff writers
Posted on 04 Jan 2012
A gene has been detected that is linked to epilepsy in babies and movement disorders in older children. More...


The gene has been associated with the rare childhood neurological disorder known as paroxysmal kinesigenic dyskinesia with infantile convulsions or PKD/IC.

A large international team led by scientists at the University of California, San Francisco (UCSF; USA) studied ways that could help to improve the diagnosis of PKD/IC and may also help to explain other movement disorders, such as Parkinson's disease. The team has identified a perplexing gene in the brain called proline-rich transmembrane protein 2 (PRRT2). No knowledge exists about the function or ability of this gene, which bears little resemblance to anything else in the human genome.

The scientists conducted the study on a cohort of 103 families, which included one or more members with the PKD/IC manifestation. The investigators identified mutations in the PRRT2 gene that is present in the brain and spinal cord, during genetic testing of the families. The mutation causes the proteins that the PRRT2 gene encodes to shorten or to completely disappear from the individual's brain and spinal cord. According to the investigative team, the neurological symptoms may be caused due to a loss of neuronal regulation, meaning that when the genetic mutations cause the gene products to disappear, the nerve cells, which normally appear in those locations, may become overly excited, firing signals too frequently or strongly, which leads to the involuntary movements.

Louis Ptacek, MD, the senior author of the study, said, "This is both exciting and a little bit scary. Understanding the underlying biology of this disease is absolutely going to help us understand movement disorders in general." PKD/IC is a rare disorder in infants with epileptic seizures, affecting approximately one in every 100,000 children in the US, according to Prof. Ptacek's estimation. It commonly disappears within a year or two but often reemerges later in childhood as a movement disorder, which is characterized by sudden, startling, involuntary jerks when the children start moving. In some children just the thought of moving will cause them to jerk involuntarily. The disease is classified as idiopathic, which, is basically just another way of saying the cause is unknown. The study was published in the January 2012 issue of Cell Reports.

UCSF


Related Links:

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Specimen Radiography System
TrueView 200 Pro
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.